Penumbra's THUNDERBOLT Shows Strong Efficacy in Stroke Study…

Event summary

Penumbra's THUNDERBOLT achieved 87.5% successful reperfusion in ELVO stroke patients.
Study showed 70.4% of cases reached mTICI 2c-3, linked to better recovery outcomes.
Median time-to-revascularization was 20 minutes with a 2.8% serious adverse event rate.
THUNDERBOLT received FDA clearance and CE Mark in 2026.

The big picture

Penumbra's THUNDERBOLT represents a significant advancement in mechanical thrombectomy, addressing the critical need for faster and more effective clot removal in stroke patients. With acute ischemic stroke affecting millions globally, this technology could expand treatment options and improve patient outcomes. The study results position Penumbra to strengthen its dominance in the neurothrombectomy market.

What we're watching

Market Adoption: How quickly THUNDERBOLT will be integrated into standard stroke care protocols.
Competitive Positioning: Whether Penumbra can maintain leadership in thrombectomy technology against emerging competitors.
Revenue Impact: The pace at which THUNDERBOLT adoption will translate into meaningful revenue growth for Penumbra.